Search

This issue brief examines well-child visit rates overall and for selected characteristics before and after the pandemic began and discusses recent state and federal policy changes that could impact children’s preventive care. More than half of children under age 21 enrolled in Medicaid or CHIP received a well-child visit in 2019, but the share fell to 48% in 2020, the start of the COVID-19 pandemic.

In this Monitor, we explore how ongoing misinformation about the safety and efficacy of COVID-19 vaccines may affect the acceptance of new vaccine recommendations. First, we examine the false and misleading claims underlying the Kansas Attorney General’s lawsuit against Pfizer. We also discuss the CDC’s most recent vaccine.

This Monitor highlights April KFF Tracking Poll findings on perceptions about measles and explores the unsubstantiated promotion of budesonide and clarithromycin as treatments. It also covers misrepresentations of syringe programs and how prompting strategies can boost the accuracy of AI chatbots on health questions.

With health officials reporting 800 measles cases in multiple states already this year, most of the public – and most parents – report hearing at least one false claim about measles or the vaccine for it, and many of them aren’t sure what to believe, the latest KFF Tracking Poll…

This poll looks at awareness and concern over the outbreak of measles in the U.S. and finds that a growing share of adults is encountering false claims about the measles vaccines, but many are uncertain whether these claims are true or false. Parents who lean toward believing the false claims are less likely to say they keep their children up to date on routine vaccinations.

House Republicans have passed a reconciliation package (the “One Big Beautiful Bill Act”) that would make significant changes to Medicaid and the Affordable Care Act (ACA) Marketplaces and increase the number of people without health insurance by an estimated 10.9 million. This analysis estimates state-level increases in the number of uninsured people due to this legislation, along with other changes to the Marketplace, including the expiration of the enhanced premium tax credits.

The Medicare Part D program provides an outpatient prescription drug benefit to more than 50 million older adults and people with long-term disabilities in Medicare who enroll in private plans, including stand-alone prescription drug plans (PDPs) to supplement traditional Medicare and Medicare Advantage prescription drug plans (MA-PDs) that include drug coverage and other Medicare-covered benefits. This brief analyzes Medicare Part D enrollment and costs in 2025 and trends over time, based on data from the Centers for Medicare & Medicaid Services (CMS).

This brief focuses on the stand-alone Medicare Part D prescription drug plan marketplace and its somewhat uncertain future, in light of recent trends in plan availability and the potential for another year of premium increases in 2026, in part depending on what the Trump administration decides to do with the temporary Part D premium stabilization demonstration. The brief explains why the stability of the PDP market matters, both for people in traditional Medicare who want prescription drug coverage but also for the viability of traditional Medicare as an option vis a vis Medicare Advantage.

Under the Senate-passed reconciliation bill, federal Medicaid spending in rural areas is estimated to decline by $155 billion, more than in the House-passed bill, and far more than the $50 billion appropriated for the rural health fund.

Nearly half of adults say that they will “definitely” or “probably” get the newly recommended COVID-19 vaccine, though most parents are not planning to get the shot for their children, according to the latest KFF COVID-19 Vaccine Monitor poll. Among all adults, 23% say they will definitely get the new…